Guillain-Barré syndrome (GBS) is a rare but serious autoimmune disorder in which the body's immune system attacks the peripheral nervous system. This can lead to muscle weakness, paralysis, and in severe cases, difficulty breathing or even death. The exact cause of GBS is unknown, but it is often triggered by an infection, such as a respiratory or gastrointestinal illness. Symptoms of GBS can vary widely, but typically include numbness or tingling in the extremities, muscle weakness, and difficulty coordinating movements. The condition can progress rapidly, with some cases reaching their peak severity within a few days. Treatment for GBS often involves supportive care, such as physical therapy to help regain strength and mobility, as well as medications to reduce inflammation and manage symptoms. In some cases, more aggressive treatments, such as plasma exchange or intravenous immunoglobulin therapy, may be necessary. Research into GBS is ongoing, with a focus on better understanding the underlying causes of the disorder, improving diagnostic techniques, and developing more effective treatments. Early diagnosis and treatment can greatly improve outcomes for individuals with GBS.